Research programme: vascular disease therapy - Progen Pharmaceuticals
Latest Information Update: 24 Jul 2008
At a glance
- Originator Cellgate
- Developer Progen Pharmaceuticals Inc
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Vascular restenosis
Most Recent Events
- 24 Jul 2008 Discontinued - Preclinical for Vascular restenosis in USA (unspecified route)
- 09 Aug 2007 Preclinical trials in Vascular restenosis in USA (unspecified route)